JPMorgan lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $10 from $11 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Largest borrow rate increases among liquid names
- Recursion Pharmaceuticals Names New Chief Medical Officer
- Recursion Pharmaceuticals announces Vicki Goodman as chief medical officer
- Insiders Cash Out: GE Vernova, Recursion, Axon, Seagate, Energy Fuels
- Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum